Press releasePRNewswire
Eagle Pharmaceuticals
EGRX · OTC
$0.885−$0.705 (−44.34%)TodayMarket closed ·
Prev close $1.59
Latest news
- Press releasePRNewswire
HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
- Press releaseGlobe Newswire
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
- Press releaseGlobe Newswire
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
- Press releaseGlobe Newswire
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
- Press releaseGlobe Newswire
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan
- Press releaseGlobe Newswire
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
- Press releaseGlobe Newswire
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer
- Press releaseGlobe Newswire
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
- NewsAvi Kapoor
Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings
- NewsAvi Kapoor
Dow Gains 100 Points; Joby Aviation Shares Spike Higher
- NewsAvi Kapoor
US Stocks Edge Lower; Private Employment Beats Expectations
- Press releaseGlobe Newswire
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.